BCR and leukemia: We reported that stimulation of the normal ABL1 kinase by a chemical compound DPH [24] enhanced anti-leukemia effect of TKIs such as imatinib and ponatinib in human and murine leukemias expressing BCR-ABL1, TEL-ABL1 and NUP214-ABL1 [11].